Cold ischemia (CI)-warm reperfusion (WR) liver injury remains a problem in
liver transplantation. CI-WR initially causes sinusoidal endothelial cell (SEC) apoptosis through a
caspase-dependent mechanism. We previously showed that the
caspase inhibitor
IDN-1965 prevents CI-WR-induced SEC apoptosis. However, this agent required to be administered to the donor, preservation
solution, and recipient for efficacy. Here, we show that a second-generation
caspase inhibitor,
IDN-6556, effectively prevents CI-WR-induced SEC injury when added only to University of Wisconsin (UW) cold storage media. Rat livers were stored in
UW solution for 24 hours at 4 degrees C and reperfused for 1 hour at 37 degrees C. Apoptosis was quantitated using terminal deoxynucleotide transferasemediated
deoxyuridine triphosphate nick end labeling (TUNEL) assay and
caspase 3 activation determined by biochemical measurement and immunohistochemical analysis. Pan-
caspase inhibitors (IDN-8066, IDN-7503, IDN-7436, IDN-1965, and IDN-6556) were applied at preischemic, cold preservation, or reperfusion periods. TUNEL-positive SEC and
caspase 3-like activity in the liver was increased by CI-WR. Three
caspase inhibitors (IDN-8066, IDN-1965, and IDN-6556) effectively attenuated SEC apoptosis and
caspase 3 activation. The most potent inhibitor,
IDN-6556, reduced SEC apoptosis and
caspase 3 activity by 55% and 94%, respectively. Prevention of SEC apoptosis by
IDN-6556 was not reduced when this agent was administered only during the cold preservation period. When added to the preservation
solution, the
caspase inhibitor
IDN-6556 appears to be a feasible therapeutic agent against
ischemia-reperfusion injury in
liver transplantation.